论文部分内容阅读
目的:探讨P-糖蛋白(P-gp)、多药耐药相关蛋白(MRP)、肺耐药相关蛋白(LRP)和乳腺耐药蛋白(BCRP)在肺癌中的表达及其临床意义。方法:利用组织芯片技术和免疫组织化学二步法,对86例行术后辅助化疗的早期非小细胞肺癌标本进行上述4种膜转运蛋白检测。结果:在肺癌组织中P-gp、MRP、LRP、BCRP表达的阳性率分别为70.9%、73.3%、79.1%和39.5%,其表达与临床病理类型无关(P>0.05);术后化疗效果不佳患者MRP、BCRP的表达水平高于术后化疗效果佳患者,但差异无显著性(P>O.05);P-gp、LRP的表达水平与肺癌耐药及预后有关(P<0.05)。结论:P-gp、MRP、LRP、BCRP在未化疗过的肺癌组织中均有不同程度的表达,且与肺癌的某些生物学行为有关,联合检测P-gp、LRP有助于早期肺癌术后辅助化疗的选择及预后的判断。
Objective: To investigate the expression and clinical significance of P-glycoprotein, multidrug resistance-related protein (MRP), lung resistance-related protein (LRP) and breast resistance protein (BCRP) in lung cancer. Methods: Tissue microarray technique and immunohistochemical two-step method were used to detect the expression of the above four membrane transporters in 86 patients with early-stage non-small cell lung cancer after adjuvant chemotherapy. Results: The positive rates of P-gp, MRP, LRP and BCRP in lung cancer tissues were 70.9%, 73.3%, 79.1% and 39.5%, respectively. The positive rates of P-gp, The expression levels of MRP and BCRP in patients with poor prognosis were higher than those in patients with advanced chemotherapy, but there was no significant difference (P> 0.05). The expression of P-gp and LRP was correlated with drug resistance and prognosis ). Conclusions: P-gp, MRP, LRP and BCRP are all expressed in different degree in non-chemotherapy lung cancer tissues, and are related to some biological behaviors of lung cancer. Combined detection of P-gp and LRP may be helpful for early lung cancer surgery Postoperative Adjuvant Chemotherapy and Prognosis.